Individually Neuronavigated accelerated intermittent theta burst stimulation with MagPro X100
Individually Neuronavigated accelerated intermittent theta burst stimulation with MagPro X100: Magpro X100, Axilium Cobot, Localite Camera
Study summary
This proposal seeks to carry out an open-label single arm study to examine the neurobehavioral changes induced by personalized, causal network mapping guided accelerated intermittent theta burst stimulation (aiTBS) in patients with treatment-resistant anxiety-related disorders.
Eligibility
Sex
ALL
Min age
21 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Male/ female aged ≥ 21 years and ≤ 70 years
* Diagnosis of an anxiety-related disorder as validated by the MINI (Specifically, the types of anxiety-related disorders are: generalized anxiety disorder; panic disorderl social anxiety disorder; obsessive compulsive disorder; post-traumatic stress disorder; agoraphobia; anxiety disorder due to another medical condition; other specified anxiety disorders; and unspecified anxiety disorder.)
* Non-response to adequate trial (4 weeks) of at least two anxiety medication as verified by the study clinician, or psychotherapy for anxiety
* BAI score of 16 or above
* Able to give informed consent
* Able to understand English
Exclusion Criteria:
* DSM-5 psychotic disorder
* Significant personality disorder which may hinder the progress of this study
* Drug or alcohol abuse or dependency (preceding 3 months)
* Rapid clinical response required, e.g., high suicide risk
* Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy
* Metal in the cranium, skull defects, pacemaker, cochlear implant, medication infusion pumps or any other electronic implants/ devices
* Tattoos containing derromagnetic ink or permanent piercings
* Currently wearing dental braces
* Pregnancy
* Unsuitable for MRI or TMS for any other reasons
* With recent TMS or ECT treatment within the past 3 months
* Currently on multiple stimulant medications (2 or more)
* Participant does not have the capacity to provide consent
Primary outcome measure(s)
Beck Anxiety Inventory (BAI) — Baseline, immediately post-treatment, 1-month and 3-months post-intervention. The primary outcome will be the response rate as defined as ≥50% reduction from baseline BAI scores pre- and post-iTBS treatment. BAI is an ordinal self-report scale measuring physical and cognitive anxiety symptoms ranging from 0-63. Higher scores mean worse outcome.
Trial sites (1)
Facility
City
Region
Status
National University Hospital, Singapore
Singapore
Singapore
More National University Hospital, Singapore trials in Singapore
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.